SpringWorks Therapeutics, Inc. (SWTX) stock surged 7.02% in after-hours trading on Tuesday, following a major regulatory approval and potential acquisition news.
The U.S. Food and Drug Administration (FDA) approved SpringWorks' drug Gomekli (mirdametinib) for the treatment of adult and pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas that cannot be completely removed surgically. NF1 is a rare genetic disorder that causes tumors to grow on nerves throughout the body.
"In addition to a capsule, we offer a tablet that dissolves in water, which is really important for patients unable to swallow, and those who couldn't previously receive therapy," said SpringWorks CEO Saqib Islam. The approval was based on a mid-stage trial where the drug showed significant reduction in tumor volume in both pediatric and adult patients.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。